[Special Stock] Meditox's Stock Rises on Botox Dispute Victory News

[Asia Economy Reporter Geum Boryeong] Following the news that Medytox won the Botox dispute, its stock price showed strength on the morning of the 17th.

At 9:19 AM that day, Medytox's stock price recorded 233,300 KRW, up 7.96% (17,200 KRW) compared to the previous trading day.

Medytox had been in conflict with Daewoong Pharmaceutical over the source of the botulinum strain, the raw material for the botulinum toxin preparation commonly called 'Botox.' Medytox owns 'Medytoxine,' while Daewoong Pharmaceutical owns 'Nabota.'

The U.S. International Trade Commission (ITC) on the 16th (local time) ruled in favor of Medytox in the final judgment of the trade secret infringement lawsuit regarding the botulinum strain between Medytox and Daewoong Pharmaceutical.

This content was produced with the assistance of AI translation services.